CircRNA: as a disease marker potential and research strategy

Institute forTranslation Medicine, Qingdao University, Qingdao, Shandong, China
Department of Inspection, The medical faculty of Qingdao University, Qingdao University, Qingdao, Shandong, China
DOI
10.7287/peerj.preprints.26936v1
Subject Areas
Biochemistry, Cell Biology
Keywords
CircRNA, Diseases, Research strategy, Database
Copyright
© 2018 Xu et al.
Licence
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ Preprints) and either DOI or URL of the article must be cited.
Cite this article
Xu S, Zhou L, Ponnusamy M, Zhang L, Wang K. 2018. CircRNA: as a disease marker potential and research strategy. PeerJ Preprints 6:e26936v1

Abstract

Circular RNA (CircRNA) is an endogenous noncoding RNA with covalently closed cyclic structure. It is divided into exonic circRNA, intronic circRNA and exon-intron circRNA, based on their components. CircRNAs are well conserved in sequence and abundantly expressed in a tissue specific manner. They have a high stability due to resistance to exonuclease. Depends on their sequence, they perform many biological function including microRNA sponging activity, modulation of alternative splicing or transcription, interaction with RNA binding proteins, rolling translation and derivative of pseudogenes. They are involved in the development of a variety pathological condition including cardiovascular disease, diabetes, neurological diseases and cancer. Emerging evidences show that circRNA are likely to be potential targets for new clinical diagnostic markers or treatment of many diseases. In this review, we have described the potential relationship between circRNA and disease progression, methods and databases of cyclic RNA.

Author Comment

This is a submission to PeerJ for review.